CD274 and cancer: KEYNOTE-355 showed that first-line pembrolizumab plus chemotherapy (nab-paclitaxel; paclitaxel; or gemcitabine/carboplatin) improved PFS and ORR, versus chemotherapy plus a placebo, in the patients with TNBC cancers and CPS ≥ 10, using the IHC 22C3 PD-L1 assay.